Planning in a volatile environment: how will the NHS reconcile its competing priorities and operational planning to meet its challenges?

Pharma Market Access Insights - from Mtech Access

What does the ‘2022/23 priorities and operational planning guidance’ document mean for the NHS, for Integrated Care System (ICS) development and for an NHS workforce still battling COVID? How realistic and achievable are the priorities set out, and how can Pharma and Medtech best help NHS leaders to achieve these goals?
Caroline Dawe (Deputy Director of Commissioning, Bristol, North Somerset and South Gloucestershire Clinical Commissioning Group [CCG]) joins Tom Clarke (Director, Mtech Access) to explore all this and more.
The episode was first released live as a webinar on Friday 28th January 2022. Learn more about this webinar at: https://mtechaccess.co.uk/nhs-2022-23-priorities-operational-planning-guidance-webinar/

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Capíttulos

1. Can you give us an idea of the various guidance documents you are working with in your Clinical Commissioning Group (CCG)? (00:05:15)

2. What impact do you expect vaccination targets to have on your system? (00:10:40)

3. How are national priorities prioritised locally? (00:12:52)

4. Is there a tension between the guidance, which is perceived to be a return to central performance management, and the integration agenda? (00:19:01)

5. Can you explain the difference between recurrent and non-recurrent funding? (00:24:28)

6. One of the priority areas in the guidance is to 'make the best use of resources' - what does this mean to you and your colleagues? (00:27:53)

7. When implementing something new, is your starting point 'let's do this the best way we can' or is it 'let's do this in the most cost-effective way'? (00:30:31)

8. What are the biggest challenges in getting treatments to move from hospital to the community? (00:33:31)

9. How prevalent is systems thinking amongst NHS leaders? (00:41:25)

10. What allows change to occur? / How do you overcome blockers? (00:46:29)

11. How do you expect to innovate, with the multiple levels of guidance in place at the moment? (00:49:48)

12. Will you see more targeted programmes of work as you get a greater understanding of your population health landscape? (00:52:57)

13. Would you look to industry (Pharma / Medtech) to help drive innovation in the NHS? (00:54:18)